Japan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.
Patients were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding themselves. Researchers typically urge caution in evaluating a study until the full results are released. But the initial findings appear to be"quite robust" and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.
Alzheimer's has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don't fully understand what causes the disease. Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Stocks making the biggest moves premarket: Biogen, Thor Industries, Lyft and moreThese are the stocks posting the largest moves before the bell.
続きを読む »
Biogen to Pay $900M to Settle Physician Kickback AllegationsBiogen, Inc, has settled allegations of kickbacks involving three MS drugs for $900M. The former employee who filed the lawsuit back in 2012 will personally receive $226M, the largest whistleblower payment on record. MedTwitter
続きを読む »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
続きを読む »
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician PaymentsBiogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to prescribe the company’s drugs, the Justice Department said
続きを読む »
Biogen to pay $900M to settle allegations of improper physician kickbacksBiogen is accused of causing submissions of false claims to Medicare and Medicaid by paying physicians kickbacks to prescribe its multiple sclerosis drugs Avonex, Tysabri and Tecfidera.
続きを読む »
Alzheimer's drug study yields positive results, say makers Eisai and BiogenAn experimental Alzheimer's drug made by Eisai Co. Ltd. and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
続きを読む »